FERRARI, PATRIZIA,BIANCHI, GIUSEPPE,FERRANDI, MARA
申请号：
NZ59441210
公开号：
NZ594412A
申请日:
2010.03.18
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
Disclosed herein is the use of 17-?-(3-furyl) and (4-pyridazinyl)-5-?, 14-?-androstane compounds of formula (I), for the manufacture of a medicament useful in the treatment of proteinuria, glomerulosclerosis and renal failure, wherein the substituents are as defined within the specification. Examples of particularly preferred compounds include: 17-?-(3-furyl)-5-?-androstane-3-?, 14-?, 17-?-triol； 3-?-(2-hydroxyethoxy)-17-?-(3-furyl)-5-?-androstane-14-?, 17-?-diol； 3-?-(2-aminoethoxy)-17-?-(3-furyl)-5-?-androstane-14-?, 17-?-diol； 3-?-(3-aminopropoxy)-17-?-(3-furyl)-5-?-androstane-14-?, 17-? -diol； 3-?-(2-methylaminoethoxy)-17-?-(3-furyl)-5-?-androstane-14-?, 17-?-diol； 3-?-(2-(1-pyrrolidinyl)ethoxy)-17-?-(3-furyl)-5-?-androstane-14-?, 17-?-diol； 3-?-(3-(1-pyrrolidinyl)propoxy)-17-?-(3-furyl)-5-?-androstane-14-?, 17-?-diol； 3-?-(2-(1-imidazolyl)ethoxy)-17-?-(3-furyl)-5-?-androstane-14-?, 17-?-diol； 3-?-(2-(2-imidazolin-2-yl)ethoxy)-17-?-(3-furyl)-5-?-androstane-14-?, 17-?-diol.
